<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02332889</url>
  </required_header>
  <id_info>
    <org_study_id>14.0855</org_study_id>
    <nct_id>NCT02332889</nct_id>
  </id_info>
  <brief_title>Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs</brief_title>
  <official_title>A Phase I/Pilot II Trial Combining Decitabine and Vaccine Therapy for Patients With Relapsed or Refractory Pediatric High Grade Gliomas, Medulloblastomas, and Central Nervous System Primitive Neuroectodermal Tumors (CNS PNETs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine the safety of using the combination of&#xD;
      decitabine and a cancer vaccine plus Hiltonol. The vaccine will be made from the subject's&#xD;
      blood cells and is designed to interact in the subject's body with cells that are programmed&#xD;
      to fight specific tumor proteins NY-ESO-1, Melanoma Antigen Gene-A1 (MAGE-A1) and Melanoma&#xD;
      Antigen Gene-A3 (MAGE-A3). The decitabine will be given to increase the amount and activity&#xD;
      of these cancer proteins on the surface of tumor cells to increase the possibility that the&#xD;
      vaccine will stimulate cells to act against the tumor cells. Subjects will be assessed to&#xD;
      determine how these tumors respond to the treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the challenges of the practical application of immunotherapy for brain tumors is the&#xD;
      lack of expression of tumor antigens as well as the down-regulation of Major&#xD;
      Histocompatibility Complex (MHC Class I and II ) molecules, which are needed for antigen&#xD;
      presentation. Considering the ability of 5-aza-2-deoxycytidine (DAC) to facilitate the&#xD;
      expression of cancer/testis (CT) antigens and major histocompatibility complex molecules&#xD;
      (MHC) and the fact that it has good blood brain barrier penetration, it is reasonable to test&#xD;
      this approach in a vaccine study for patients who have experienced disease recurrence. The&#xD;
      use of a combined approach to tumor immunotherapy - antigen upregulation followed by&#xD;
      vaccination - has not been studied in this patient population, and there is a strong biologic&#xD;
      rationale for this strategy.&#xD;
&#xD;
      Patients with pediatric brain tumors (medulloblastoma, CNS PNET, high grade glioma) who have&#xD;
      experienced disease relapse or progressive refractory disease will be eligible. Each cycle&#xD;
      will consist of DAC at low dose administered over a 5 day period, followed by two weekly&#xD;
      vaccinations consisting of autologous dendritic cells pulsed with pooled, overlapping peptide&#xD;
      mixes derived from full-length MAGE-A1, MAGE-A3, and NY-ESO-1. This dose of DAC is lower than&#xD;
      all previously reported doses that have been safely administered in adult patients with&#xD;
      Myelodysplastic syndromes (MDS) and Acute myeloid leukemia (AML), and was used in a previous&#xD;
      protocol for relapsed and refractory pediatric neuroblastoma and sarcomas. A novel way of&#xD;
      stimulating CD4 and CD8 antigen specific T cells is to use a dendritic cells (DC) vaccine&#xD;
      approach in which the cells are pulsed with overlapping peptides derived from these antigens,&#xD;
      so that patients from several different HLA backgrounds can be enrolled. Overlapping peptide&#xD;
      mixes derived from full-length NY-ESO-1, MAGE-A1, or MAGE-A3 have been acquired and consists&#xD;
      of 15-mers, with 11 amino acid overlap. The number of DC given in our study (8-10 x 106&#xD;
      peptide pulsed DC) is within the range of doses given in previous studies. Vaccinations are&#xD;
      spaced at weekly intervals, based on multiple previous studies in which this approach is&#xD;
      taken, and the fact that in vitro re-stimulation of cytolytic T lymphocyte (CTL) generally&#xD;
      occurs on a weekly basis. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is given&#xD;
      days 1 through 5 during vaccine weeks, to minimize leukopenia from DAC and to help facilitate&#xD;
      antigen presenting cell function. The adjuvant poly-interstitial Cajal-like cell (ICLC;&#xD;
      Hiltonol) will be injected immediately after and adjacent to DC vaccine site to enhance DC&#xD;
      maturation. We will accrue 10 patients with relapsed, refractory, or progressive pediatric&#xD;
      brain tumors over a 3 year period. Cycles will repeat every five weeks, for two cycles.&#xD;
      Patients who do not have disease progression after two cycles may receive an additional two&#xD;
      cycles of therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Transition to a different immunotherapy strategy in the future at our institution&#xD;
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability (Number of Participants Without Adverse Events)</measure>
    <time_frame>20 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Gliomas</condition>
  <condition>Medulloblastoma</condition>
  <condition>Neuroectodermal Tumors, Primitive</condition>
  <arm_group>
    <arm_group_label>Decitabine/Vaccine Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological/Vaccine: Vaccine (autologous dendritic cells) and Drug: Decitabine and Hiltonol</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccine (autologous dendritic cells)</intervention_name>
    <description>Prior to vaccination, DC will be thawed, washed once with normal saline containing 1% human serum albumin, and viability will be checked (must be &gt; 70%). Peptide pulsed DC will be placed in 1 ml tuberculin syringe(s) and transferred to the study physician for vaccination</description>
    <arm_group_label>Decitabine/Vaccine Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine and Hiltonol</intervention_name>
    <description>Patients will receive DAC at a dose of 10 mg/m2/d intravenously (IV) over one hour on days 1-5 of week 1. Hiltonol will be given intramuscularly at the same site immediately following vaccine</description>
    <arm_group_label>Decitabine/Vaccine Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Criteria for enrollment:&#xD;
&#xD;
          -  Relapsed medulloblastoma, CNS PNET, or high grade glioma. Confirmatory biopsy is&#xD;
             required at time of initial diagnosis.&#xD;
&#xD;
          -  Because of rapid clinical progression and decline at time of relapse in patients with&#xD;
             grade IV gliomas and diffuse intrinsic pontine gliomas (DIPGs), and the 4-6 weeks&#xD;
             required to develop vaccine, patients with these tumors will be eligible to enroll and&#xD;
             have DCs harvested and stored at the time of diagnosis, but will not be treated with&#xD;
             vaccine until time of relapse.&#xD;
&#xD;
          -  Age: Patients must be 2 to 25 years of age.&#xD;
&#xD;
        Criteria for treatment:&#xD;
&#xD;
          -  The patient must have experienced relapsed, progressive, or refractory disease.&#xD;
&#xD;
          -  The patient may have gross tumor that has been treated with chemotherapy or radiation&#xD;
             prior to study treatment.&#xD;
&#xD;
          -  The patient must have received standard therapy for their tumor.&#xD;
&#xD;
          -  The patient must be at least 90 days from primary radiotherapy.&#xD;
&#xD;
          -  Hematologic Function: absolute neutrophil (ANC): 1000/uL; Platelet count: 75,000/uL.&#xD;
&#xD;
          -  Renal Function: Creatinine clearance or radioisotope glomerular filtration rate (GFR)&#xD;
             70ml/min/1.73 m2 .&#xD;
&#xD;
          -  Cardiac Function: Patient must have normal cardiac function documented by:&#xD;
&#xD;
          -  Ejection fraction (&gt;55%) documented by echocardiogram or radionuclide multigated&#xD;
             acquisition (MUGA) scan evaluation OR&#xD;
&#xD;
          -  Fractional shortening (â‰¥28%) documented by echocardiogram&#xD;
&#xD;
          -  Liver Function: Total bilirubin 1.5x normal for age, and serum glutamate pyruvate&#xD;
             transaminase (SGPT (ALT)) and serum glutamate oxaloacetate transaminase (SGOT (AST))&#xD;
             3x normal for age.&#xD;
&#xD;
          -  Room air pulse oximetry &gt;94%.&#xD;
&#xD;
          -  Male and female sexually active patients of reproductive age who wish to participate&#xD;
             must agree to use acceptable contraception.&#xD;
&#xD;
          -  Lansky/Karnofsky performance scale &gt; 50, electrocorticogram (ECOG) &lt; or = 2 (Appendix&#xD;
             I).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is pregnant.&#xD;
&#xD;
          -  Patients with a positive result for any of the following diagnostic tests: Hep B Ag,&#xD;
             Hep B Core Ab, Hep C Ab, HIV-1 Ab, HIV-2 Ab, human T-cell leukemia virus (HTLV-1 Ab),&#xD;
             HTLV-2 Ab, rapid plasma reagin (RPR).&#xD;
&#xD;
          -  Patient has a history of autoimmune disease, specifically inflammatory bowel disease,&#xD;
             systemic lupus erythematosis, or rheumatoid arthritis.&#xD;
&#xD;
          -  Patient is receiving high doses of systemic corticosteroids or concurrent chemotherapy&#xD;
             at the time of beginning study treatment. (Maximum dose of dexamethasone allowed is&#xD;
             0.1mg/kg/day not to exceed 4mg/day.)&#xD;
&#xD;
          -  Patient has a known systemic hypersensitivity to DAC, Hiltonol, or any vaccine&#xD;
             component.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth G Lucas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pediatric Hematology/Oncology University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville, Kosair Children's Charities Pediatric Clinical Research Unit</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>October 20, 2014</study_first_submitted>
  <study_first_submitted_qc>January 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2015</study_first_posted>
  <results_first_submitted>December 14, 2017</results_first_submitted>
  <results_first_submitted_qc>March 29, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2018</results_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Poly ICLC</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Decitabine/Vaccine Therapy</title>
          <description>Biological/Vaccine: Vaccine (autologous dendritic cells) and Drug: Decitabine and Hiltonol&#xD;
Vaccine (autologous dendritic cells [DC]): Prior to vaccination, DC will be thawed, washed once with normal saline containing 1% human serum albumin, and viability will be checked (must be &gt; 70%). Peptide pulsed DC will be placed in 1 ml tuberculin syringe(s) and transferred to the study physician for vaccination&#xD;
Decitabine and Hiltonol: Patients will receive 5-aza-2-deoxycytidine (DAC) at a dose of 10 mg/m2/d intravenously (IV) over one hour on days 1-5 of week 1. Hiltonol will be given intramuscularly at the same site immediately following vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Decitabine/Vaccine Therapy</title>
          <description>Biological/Vaccine: Vaccine (autologous dendritic cells) and Drug: Decitabine and Hiltonol&#xD;
Vaccine (autologous dendritic cells): Prior to vaccination, DC will be thawed, washed once with normal saline containing 1% human serum albumin, and viability will be checked (must be &gt; 70%). Peptide pulsed DC will be placed in 1 ml tuberculin syringe(s) and transferred to the study physician for vaccination&#xD;
Decitabine and Hiltonol: Patients will receive DAC at a dose of 10 mg/m2/d intravenously (IV) over one hour on days 1-5 of week 1. Hiltonol will be given intramuscularly at the same site immediately following vaccine</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tolerability (Number of Participants Without Adverse Events)</title>
        <time_frame>20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Decitabine/Vaccine Therapy</title>
            <description>Biological/Vaccine: Vaccine (autologous dendritic cells) and Drug: Decitabine and Hiltonol&#xD;
Vaccine (autologous dendritic cells): Prior to vaccination, DC will be thawed, washed once with normal saline containing 1% human serum albumin, and viability will be checked (must be &gt; 70%). Peptide pulsed DC will be placed in 1 ml tuberculin syringe(s) and transferred to the study physician for vaccination&#xD;
Decitabine and Hiltonol: Patients will receive DAC at a dose of 10 mg/m2/d intravenously (IV) over one hour on days 1-5 of week 1. Hiltonol will be given intramuscularly at the same site immediately following vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability (Number of Participants Without Adverse Events)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Decitabine/Vaccine Therapy</title>
          <description>Biological/Vaccine: Vaccine (autologous dendritic cells) and Drug: Decitabine and Hiltonol&#xD;
Vaccine (autologous dendritic cells): Prior to vaccination, DC will be thawed, washed once with normal saline containing 1% human serum albumin, and viability will be checked (must be &gt; 70%). Peptide pulsed DC will be placed in 1 ml tuberculin syringe(s) and transferred to the study physician for vaccination&#xD;
Decitabine and Hiltonol: Patients will receive DAC at a dose of 10 mg/m2/d intravenously (IV) over one hour on days 1-5 of week 1. Hiltonol will be given intramuscularly at the same site immediately following vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Progressive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nancy Alsip</name_or_title>
      <organization>University of Louisville</organization>
      <phone>5028522905 ext 502</phone>
      <email>nancy.alsip@louisville.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

